Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).
In a new article from the NCI concerning the January 2020 approval of Ayvakit, (produced by Blueprint Medicines) the Life Raft Group is acknowledged in the section, “Capturing the Patient Experience.” We are proud to have played a role in supporting the research involved in bringing a new treatment to market for GIST patients.
David Epstein, LRG Pro Bono HR Consultant, Honored as a Leader The Life Raft Group is fortunate to have many volunteers who provide vital services to our organization pro bono. Not only are these [...]
Norman Scherzer was invited to speak at three prestigious events this spring; participating in a roundtable discussion, presenting a cancer survival plan, and speaking to a patient advocacy group. As a direct [...]
PDF is available of LRG Science to print here. An oncologist in Chennai, India, 8,366 miles away from the Life Raft Group’s Wayne, New Jersey office, is running out of treatment [...]
PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]
Caring for a loved one is filled with day-to-day stressors. But what about the stressors that are out of the ordinary? Any hospitalization is stressful. Preparing for the hospital to the extent possible can [...]
With the start of a new year, there is an opportunity to make positive changes. Cancer patients face dramatic change in their lives, and chances are they have already experienced a time of reflection [...]
Everywhere you turn, the sights and sounds of the holiday season assail you. Before the Halloween candy is sorted and the Thanksgiving turkey is cold, we are reminded of what some call “the most [...]
Our Global Consultant, Piga Fernández, Executive Director of Fundación GIST Chile has asked us to help support the passage of the National Cancer Law in Chile. In 2020, cancer will be the number one cause of death [...]